Sandoz’ US Chromatography Patent Win Holds – With A Tweak

Sandoz’ purification process for filgrastim-based biosimilars does not infringe Amgen’s process patent, the US Court of Appeals has confirmed. But in doing so, the court has rowed back on its most strident statement about the use of the doctrine of equivalents.